Leonard G. Gomella, MD, FACS, led the “Next Generation Therapeutic Layering and Sequencing” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.
Read More
Josh Mailman, MBA, the president of NorCal CarciNET, discusses the management of neuroendocrine tumors (NETs) through a patient’s perspective. He reports on overall patients’ attitudes toward Gallium Ga 68-DOTATATE imaging and the newly-approved Lutetium Lu 177 Dotatate therapy, as well as advocacy in the NETs patient community.
Read More
Arturo Loaiza-Bonilla, MD, MSEd, FACP, explains the basic scientific concepts behind neuroendocrine tumors (NETs), as well as classifying and staging these cancers. He then discusses the rationale behind targeting somatostatin receptors in NETs, therapy options, and future research in this setting.
Read More
Michael S. Cookson, MD, MMHC, describes how urologists can use American Urological Association (AUA) guidelines to better manage metastatic castration resistant prostate cancer (mCRPC) patients. He stresses the importance of urologists serving as the primary caregiver, the multidisciplinary care model, and organized sequencing of treatments and therapeutics.
Read More
Leonard G. Gomella, MD, FACS, discusses bone health issues related to prostate cancer, specifically androgen deprivation therapy (ADT) induced osteoporosis, bone resorptive therapies, such as bisphosphonates and denosumab, and morbidity and mortality associated with men who manifest bone-positive metastatic prostate cancer.
Read More